Akebia Therapeutics Inc. buy Piper Sandler
Start price
14.03.25
/
50%
€1.97
Target price
14.03.26
€5.53
Performance (%)
-48.25%
Price
05.03.26
€1.05
This prediction will end soon
Summary
This prediction is currently active. Massive losses of -48.25% have been the result for the BUY prediction by Piper_Sandler. This prediction currently runs until 14.03.26. The prediction end date can be changed by Piper_Sandler at any time. Piper_Sandler has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Akebia Therapeutics Inc. | -6.020% | -6.020% |
| iShares Core DAX® | -3,81 % | -1,47 % |
| iShares Nasdaq 100 | 0,49 % | 2,21 % |
| iShares Nikkei 225® | -4,42 % | 4,97 % |
| iShares S&P 500 | 0,25 % | 1,23 % |
Comments by Piper_Sandler for this prediction
In the thread Akebia Therapeutics Inc. diskutieren
Akebia Therapeutics, Inc. (NASDAQ: AKBA) had its price target raised by analysts at Piper Sandler from $4.00 to $6.00. They now have an "overweight" rating on the stock.
Ratings data for AKBA provided by MarketBeat
Stopped prediction by Piper_Sandler for Akebia Therapeutics Inc.
Akebia Therapeutics Inc.
Start price
Target price
Perf. (%)
€1.29
06.02.26
06.02.26
€3.39
06.02.27
06.02.27
-20.61%
05.03.26
05.03.26
Akebia Therapeutics Inc.
Start price
Target price
Perf. (%)
€0.92
31.05.23
31.05.23
-
31.05.24
31.05.24
13.76%
01.06.24
01.06.24